Status:
COMPLETED
Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer
Lead Sponsor:
Stanford University
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study has two primary objectives. The first objective is to determine the maximal tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with inoperable malignant l...
Eligibility Criteria
Inclusion
- Lung tumor \>= 5.0 cm.
- Age \> 18 years,
- Histologic confirmation of malignancy (primary lung or metastatic tumor)
- Deemed unresectable either by radiographic criteria (such as direct invasion of the mediastinum, heart, great vessels, or trachea), by virtue of excessive risk to patient, patient refusal to undergo surgery, or prior operative findings.
- Performance status of 0-2 by Eastern Clinical Oncology Group criteria
Exclusion
- No chemotherapy within 2 weeks of radiation treatment.
- 2\. Refusal to sign informed consent.
- 3\. Refusal to take a pregnancy test prior to treatment if the patient is a woman with child bearing potential.
Key Trial Info
Start Date :
March 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00238602
Start Date
March 1 2000
End Date
June 1 2012
Last Update
July 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305